公开(公告)号：US09655881B2

公开(公告)日：2017-05-23

申请号：US15388834

申请日：2016-12-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/14 ,  A61K31/4035

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09315458B2

公开(公告)日：2016-04-19

申请号：US14693342

申请日：2015-04-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D403/10 ,  C07D405/14 ,  C07D403/04 ,  C07D401/10 ,  C07D401/14

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供了具有胆碱能毒蕈碱M1受体阳性变构调节剂活性的化合物，可用作预防或治疗阿尔茨海默病，精神分裂症，疼痛，睡眠障碍，帕金森病痴呆，路易体痴呆等。 本发明涉及由式（I）表示的化合物或其盐。 其中每个符号如说明书中所述或其盐。

公开(公告)号：US10457670B2

公开(公告)日：2019-10-29

申请号：US15830634

申请日：2017-12-04

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D405/14 ,  C07D405/04 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  A61K31/145 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D471/04 ,  C07D403/10 ,  A61K31/13 ,  A61K31/045

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09775827B2

公开(公告)日：2017-10-03

申请号：US15488002

申请日：2017-04-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D403/10 ,  C07D405/14 ,  C07D403/04 ,  C07D401/10 ,  C07D401/14 ,  A61K31/4035 ,  A61K31/445 ,  A61K31/55 ,  A61K31/325 ,  A61K31/4155 ,  A61K31/4439

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.